Latest Articles
Short-Term Vaginal Estrogen Therapy Does Not Increase Risks of Endometrial Cancer Recurrence - The ASCO Post
Short-Term Vaginal Estrogen Therapy Does Not Increase Risks of Endometrial Cancer Recurrence The ASCO Post
Published: March 5, 2026, 4:20 p.m.
Vaginal estrogen therapy not associated with increased risk of endometrial cancer recurrence - Contemporary OB/GYN
Vaginal estrogen therapy not associated with increased risk of endometrial cancer recurrence Contemporary OB/GYN
Published: March 5, 2026, 12:23 a.m.
Vaginal estrogen therapy not linked to cancer recurrence in survivors of endometrial cancer - Medical Xpress
Vaginal estrogen therapy not linked to cancer recurrence in survivors of endometrial cancer Medical Xpress
Published: March 4, 2026, 11:40 p.m.
Is Vaginal Estrogen Safe After Endometrial Cancer? - Medscape
Is Vaginal Estrogen Safe After Endometrial Cancer? Medscape
Published: March 4, 2026, 5:49 p.m.
Vaginal estrogen therapy is safe for young endometrial cancer survivors, study finds - News-Medical
Vaginal estrogen therapy is safe for young endometrial cancer survivors, study finds News-Medical
Published: March 4, 2026, 2:18 p.m.
Vaginal Estrogen Safe for Endometrial Cancer Survivors - Mirage News
Vaginal Estrogen Safe for Endometrial Cancer Survivors Mirage News
Published: March 4, 2026, 5:04 a.m.
Howard Stern, Robin Quivers, Endometrial Cancer - SurvivorNet
Howard Stern, Robin Quivers, Endometrial Cancer SurvivorNet
Published: March 4, 2026, 2:56 a.m.
Construction and initial validation of key gene network for progesterone resistance in endometrial cancer based on genome-wide CRISPR screening - Nature
Construction and initial validation of key gene network for progesterone resistance in endometrial cancer based on genome-wide CRISPR screening Nature
Published: March 3, 2026, 10:36 a.m.
6 Tips for Going Through Endometrial Cancer Treatment - Cleveland Clinic Health Essentials
6 Tips for Going Through Endometrial Cancer Treatment Cleveland Clinic Health Essentials
Published: March 3, 2026, 8:30 a.m.
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer - Defense World
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer Defense World
Published: March 2, 2026, 6:50 p.m.
Link copied to clipboard!